Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Acrivon Therapeutics, Inc. - Common Stock (NQ: ACRV ) 7.560 -0.130 (-1.69%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 86,571 Open 7.600 Bid (Size) 7.300 (10) Ask (Size) 7.670 (1) Prev. Close 7.690 Today's Range 7.400 - 7.670 52wk Range 3.190 - 13.50 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference May 29, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024 May 14, 2024 ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Performance YTD +50.90% +50.90% 1 Month +14.03% +14.03% 3 Month -28.27% -28.27% 6 Month +73.79% +73.79% 1 Year -42.60% -42.60% More News Read More Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 14, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday April 25, 2024 Via InvestorPlace Acrivon Therapeutics: Q4 Earnings Insights March 28, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session April 24, 2024 Via Benzinga Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event April 24, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 April 16, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable April 10, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire Crude Oil Down Over 1%; Cognyte Software Shares Plummet April 09, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 12 Health Care Stocks Moving In Tuesday's Intraday Session April 09, 2024 Via Benzinga Dow Dips 150 Points; Laser Photonics Shares Spike Higher April 09, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session April 09, 2024 Via Benzinga Why Is Rail Vision (RVSN) Stock Up 17% Today? April 09, 2024 Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost April 09, 2024 Via InvestorPlace Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On? April 09, 2024 Via Benzinga Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings April 09, 2024 Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's Pre-Market Session April 09, 2024 Via Benzinga Acrivon Therapeutics Announces $130 Million Private Placement Financing April 09, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 March 28, 2024 Via InvestorPlace Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights March 28, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session March 15, 2024 Via Benzinga Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 March 05, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors March 04, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference February 27, 2024 From Acrivon Therapeutics, Inc Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
